Simplifying HIV Treatment in the Presence of Drug Resistance; Preventing from the Start - Episode 12
Rapid Treatment Initiation in HIV
Focusing on the importance of rapid treatment initiation in HIV, Shauna Applin, ARNP, reviews available therapies and provides clinical insights on treatment considerations.
BIC = bictegravir
DRV = darunavir
DTG = dolutegravir
F/TAF = FTC/TAF = Emtricitabine/Tenofovir alafenamide
F/TDF = FTC/TDF = Emtricitabine/Tenofovir disoproxil fumarate
B/F/TAF = BIC/FTC/TAF = Bictegravir/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/ABC/3TC = Dolutegravir/Abacavir/Lamivudine (single tablet regimen)
DTG + F/TAF = DTG + FTC/TAF = Dolutegravir + Emtricitabine/Tenofovir alafenamide (multi-tablet regimen)
D/C/F/TAF = DRV/COBI/FTC/TAF = Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide (single tablet regimen)
DTG/3TC = Dolutegravir/Lamivudine (single tablet regimen)
CAB = Cabotegravir
CAB + RPV = Cabotegravir + Rilpivirine
Video content above is prompted by the following questions:
- Perspectives on the rate of treatment initiation for newly diagnosed HIV have shifted over the years, leading to consensus on the importance of initiating treatment quickly.
- Can you expand on the importance of a rapid start?
- What are the guideline-recommended therapies for a rapid start?
- What are the differences between them?
